Shopping Cart
- Remove All
- Your shopping cart is currently empty
Inavolisib (GDC-0077) is an orally available selective PI3Kα inhibitor with an IC50 value of 0.038 nM.It exerts its activity by binding to the ATP-binding site of PI3K, thereby inhibiting the phosphorylation of PIP2 to PIP3.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
1 mg | $80 | In Stock | |
5 mg | $223 | In Stock | |
10 mg | $392 | In Stock | |
25 mg | $668 | In Stock | |
50 mg | $1,090 | In Stock | |
100 mg | $1,890 | In Stock | |
1 mL x 10 mM (in DMSO) | $425 | In Stock |
Description | Inavolisib (GDC-0077) is an orally available selective PI3Kα inhibitor with an IC50 value of 0.038 nM.It exerts its activity by binding to the ATP-binding site of PI3K, thereby inhibiting the phosphorylation of PIP2 to PIP3. |
Targets&IC50 | PI3Kα:0.038 nM |
In vitro | METHODS: Cell viability was assayed using Inavolisib (GDC-00777) up to 100 μmol/L in a panel of cancer cell lines. RESULTS Inavolisib (GDC-00777) is a stronger cellular antiproliferative inducer. [1] |
In vivo | METHODS: p110a protein depletion was studied in a p110a mutant xenograft breast cancer model using Inavolisib (GDC-0077) at a single oral dose of 50 mg/kgDC-0077. RESULTS Inavolisib (GDC-0077) depleted p110a protein expression for up to 8 hours. [1] |
Alias | RG6114, GDC-0077 |
Molecular Weight | 407.37 |
Formula | C18H19F2N5O4 |
Cas No. | 2060571-02-8 |
Smiles | C[C@H](Nc1ccc2-c3nc(cn3CCOc2c1)N1[C@@H](COC1=O)C(F)F)C(N)=O |
Relative Density. | 1.63 g/cm3 (Predicted) |
Storage | store at low temperature,keep away from direct sunlight | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | |||||||||||||||||||||||||||||||||||
Solubility Information | DMSO: 100 mg/mL (245.48 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 10 mg/mL (24.55 mM), In vivo: Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.![]() | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
|
Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.